)
)
Aleksandra Gentry-Maharaj
Professor,
University College London
Dr Gentry-Maharaj is Principal Research Fellow, based both at the Institute of Clinical Trials & Methodology (ICTM) and Institute for Women’s Health (IfWH). Since August 2023, Dr Gentry-Maharaj is the Head of Research Department of Women’s Cancer (IfWH). The focus of the work of the department is on early detection, risk prediction and prevention of breast and gynaecological cancers.
Dr Gentry-Maharaj joined the Gynaecological Cancer Research Centre as a Research Associate in 2003, first based at Barts and since April 2004 at the Institute for Women's Health. For her entire appointment at UCL, key to the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), a randomised controlled trial involving 202,638 women from the UK which assessed the mortality impact of screening, and all the outputs of the trial. Since 2006, co-set up and coordinated the UK Ovarian cancer Population (UKOPS) study. UKOPS has contributed to the International Ovarian Cancer Association Consortium (OCAC), looking at genetic predisposition to ovarian cancer which reported the first Genome Wide Association Study for ovarian cancer. Since 2017, took on the role of the UKCTOCS Project Lead and since 2021, the role of ICON8B and Add-Aspirin Project Co-lead.
Collaborator/co-investigator on a number of grants, including The Eve Appeal and CRUK. Contributed to a EU project (7th Framework Programme, FP7) between 2007-2010. More recently, PI for a British Council grant. Since 2022, CRUK ACED Co-Director of Research Domain Trials.
Dr Gentry-Maharaj is an author on more than 205 papers in high impact journals, has contributed to numerous textbooks and reviews. She has a keen interest in education and has designed modules and programmes, some of them active since 2014. She leads the MSc Clinical Trials programme and co-leads a number of MSc and iBSc modules. Editor for BMC Women’s Health and Diagnostics.
Dr Gentry-Maharaj has presented the work at national and key international meetings (ESGO Istanbul 2005, IGCS Santa Monica 2006, ESGO Berlin 2007, IMS Madrid 2008, ESGO Nice 2015, BGCS amongst others). Over the past 15 years, she has been invited to give talks at a number of international meetings: Controversies of Ovarian Cancer Screening, University of Geneva (2009), 2nd Sino-Euro Experts Conference on Immune Biomarkers for Personalized Medicine in Oncology, Fudan University Shanghai Cancer Center, Shanghai (2015), Ovarian Cancer Academy, Cluj-Napoca, Romania (2015), Université catholique de Louvain UCLouvain, Brussels (2016), Multidisciplinary Approach to Gynecological Cancers conference, Krakow (2017).
Dr Gentry-Maharaj joined the Gynaecological Cancer Research Centre as a Research Associate in 2003, first based at Barts and since April 2004 at the Institute for Women's Health. For her entire appointment at UCL, key to the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS), a randomised controlled trial involving 202,638 women from the UK which assessed the mortality impact of screening, and all the outputs of the trial. Since 2006, co-set up and coordinated the UK Ovarian cancer Population (UKOPS) study. UKOPS has contributed to the International Ovarian Cancer Association Consortium (OCAC), looking at genetic predisposition to ovarian cancer which reported the first Genome Wide Association Study for ovarian cancer. Since 2017, took on the role of the UKCTOCS Project Lead and since 2021, the role of ICON8B and Add-Aspirin Project Co-lead.
Collaborator/co-investigator on a number of grants, including The Eve Appeal and CRUK. Contributed to a EU project (7th Framework Programme, FP7) between 2007-2010. More recently, PI for a British Council grant. Since 2022, CRUK ACED Co-Director of Research Domain Trials.
Dr Gentry-Maharaj is an author on more than 205 papers in high impact journals, has contributed to numerous textbooks and reviews. She has a keen interest in education and has designed modules and programmes, some of them active since 2014. She leads the MSc Clinical Trials programme and co-leads a number of MSc and iBSc modules. Editor for BMC Women’s Health and Diagnostics.
Dr Gentry-Maharaj has presented the work at national and key international meetings (ESGO Istanbul 2005, IGCS Santa Monica 2006, ESGO Berlin 2007, IMS Madrid 2008, ESGO Nice 2015, BGCS amongst others). Over the past 15 years, she has been invited to give talks at a number of international meetings: Controversies of Ovarian Cancer Screening, University of Geneva (2009), 2nd Sino-Euro Experts Conference on Immune Biomarkers for Personalized Medicine in Oncology, Fudan University Shanghai Cancer Center, Shanghai (2015), Ovarian Cancer Academy, Cluj-Napoca, Romania (2015), Université catholique de Louvain UCLouvain, Brussels (2016), Multidisciplinary Approach to Gynecological Cancers conference, Krakow (2017).
Sessions
-
Early Detection, Prevention and Risk Prediction of Gynaecological Cancers in Women29-Jan-2026Women & Children's Health Stage